NEW ORLEANS, April 28, 2014 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company") (NASDAQ: FURX) to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the proposed transaction, shareholders of Furiex will receive only $95.00 per share – plus up to $30.00 per share in the form of a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval – for each share of Furiex common stock that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) or associate Michael J. Palestina (michael.palestina@ksfcounsel.com) toll free at any time at 855-768-1857.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
206 Covington St.
Madisonville, LA 70447
SOURCE Kahn Swick & Foti, LLC
